Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Provides an Update on Harvest by Acreage Pharms Ltd.

Invictus MD Provides an Update on Harvest by Acreage Pharms Ltd.

 

 

Invictus MD AnINVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company"is pleased to announce that its wholly nounces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

PRESS RELEASE INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its wholly owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), completed its first two successful harvests earlier this month.  Acreage Pharms, utilizing its pesticide free growing systems, anticipates two harvests to take place the first week of September.

Trevor Dixon, CEO of Acreage Pharms commented “The yields from both of the first two harvests exceeded expectations. The additional two harvests in the first week of September will utilize the entire grow space which will maximize yields and generate sufficient data to determine anticipated annual production rates. Acreage Pharms will be in a position to receive the license to sell once the QA team has analyzed the results of the third-party lab tests. This will be a significant milestone for Acreage Pharms.”

The initial harvests in this purpose built, state-of-the-art production facility along with the highly capable, cultivation team that uses Good Production Practices, has resulted in high quality, non-irradiated medical cannabis.



INVICTUS MD STRATEGIES

The company is also pleased to report that Phase 2, a 27,800 square foot purpose built, multiple room production facility, is well under construction with scheduled completion by the end of January 2018.  Given the production improvements realized from Phase 1, the new facility is projected to produce up to 4,200 kgs per annum.  That represents a 800% increase in production over the existing production facility.  The capital costs of constructing the Phase 2 production facility is within the $6 million that was initially budgeted.

Dan Kriznic, Chairman & CEO, Invictus MD  commented “Invictus MD is well capitalized for expansion with approximately $28.5 million in cash and is prepared for an exciting year of growth. We have one of the industry’s most experienced teams and our focus remains on building our shareholder value with significant expansion plans as the demand for cannabis increases.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its wholly owned subsidiary Acreage Pharms and its non-wholly owned affiliate AB Laboratories Inc.; along with Fertilizer and Nutrients through its non-wholly owned subsidiary Future Harvest Development Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Announces Inclusion on Horizons Marijuana Life Sciences Index ETF

Invictus MD Announces Inclusion on Horizons Marijuana Life Sciences Index ETF

 

 

 Invictus MD Announces Inclusion  INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce its inclusion in the Horizon Medical

BUZ INVESTORS PRESS RELEASE  Invictus MD Announces Inclusion  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce its inclusion in the Horizon Medical Marijuana Life Sciences ETF (TSX:HMMJ) (“HMMJ ETF”), which is trading, and is the first ETF to offer direct exposure to North American-listed stocks that operate in the legal medical cannabis industry.

Horizon Medical Marijuana Life Sciences ETF is the first exchange-traded fund that offers investors direct exposure to North American-listed stocks that are involved with biopharmaceuticals, medical manufacturing, distribution, bio- products, and other businesses ancillary to the marijuana industry.  Invictus MD joins the 19 other constituents. Only stocks that meet minimum asset and liquidity thresholds are qualified for inclusion in the index, and no single stock may exceed 10% of the weight of the Index when rebalanced.




Invictus MD Announces Inclusion  

“Invictus MD’s inclusion to Horizon’s Marijuana Life Sciences Index ETF represents an important achievement for our company and recognizes the enormous efforts and successes of our team,” said Dan Kriznic, Executive Chairman. “Inclusion in the ETF will help broaden participation in Invictus MD’s shares, and improve trading liquidity for our shareholders.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR, including its wholly owned subsidiary Acreage Pharms Ltd., as well as its investment in the fully licensed facility AB Laboratories Inc.; and Fertilizer and Nutrients through Future Harvest Development Ltd .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Closes $25,008,750 Bought Deal Private Placement

Invictus MD Closes $25,008,750 Bought Deal Private Placement

Private Placement

BUZ INVESTORS PRESS RELEASE Private Placement   INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) i

BUZ INVESTORS PRESS RELEASE Private Placement   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed its previously announced bought deal private placement (the “Offering”), with Canaccord Genuity Corp., Eventus Capital Corp., Echelon Wealth Partners Inc., GMP Securities L.P. and PI Financial Corp. (collectively, the “Underwriters”), including the over-allotment option, for aggregate gross proceeds of $25,008,750. A total of 18,525,000 units (the “Units”), including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.35 per Unit.

Each Unit is comprised of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share (a “Warrant Share”) until November 24, 2018 at an exercise price of $1.75 per Warrant Share.

Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes. As compensation, the Underwriters received a commission of 5% of the gross proceeds and a corporate finance fee of 5% of the gross proceeds.



Private Placement  


All securities issued or issuable under the Offering are subject to a four-month hold period expiring on September 25, 2017.

The Company also announces the issuance of 1,000,000 common shares to an arm’s length consultant as payment for certain consulting services, including the introduction and integration of the Company’s recent acquisitions.

The Company also announces the resignation of Mike Blady from the Board.  The Company wishes to thank Mike Blady for his valuable contribution to the Company and wish him well for the future.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD announces $20,000,000 Bought Deal Private Placement of Units

Invictus MD announces $20,000,000 Bought Deal Private Placement of Units

 

 

BUZINVESTORS PRESS RELEASE Invictus MD announces INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces it has determined not to proceed

BUZINVESTORS PRESS RELEASE Invictus MD announces   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces it has determined not to proceed with its previously announced offering of convertible debentures as set forth in a news release dated April 20, 2017 and instead will proceed with an offering of units with the same underwriting syndicate.  Canaccord Genuity Corp. and Eventus Capital Corp., as co-lead underwriters and joint-bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters“), have agreed to purchase, on a bought deal private placement basis, subject to adjustment pursuant to the Underwriters’ Option (as hereinafter defined), 14,820,000 units of the Company (the “Units“), at a price of $1.35 per Unit (the “Offering Price“) for aggregate gross proceeds of $20 million (the “Offering“). Invictus MD’s board of directors determined that completing an equity financing on the terms of the Offering aligns better with the Company’s strategic objectives than the previously announced convertible debenture financing.

Invictus MD has also granted the Underwriters an option (the “Underwriters’ Option“) to purchase up to an additional 3,705,000 Units at the Offering Price, exercisable in whole or in part at any time for a period of 48 hours prior to the closing of the Offering. If the Underwriters’ Option is exercised in full, the aggregate gross proceeds of the Offering will be $25 million.



Invictus MD announces  

>>>TRADE NOW<<<

Each Unit will be comprised of one common share of the Company and one half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share (a “Warrant Share”) for a period of 18 months following the closing date of the Offering at an exercise price of $1.75 per Warrant Share. Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes.

All securities issued or issuable under the Offering will be subject to a statutory hold period lasting four months and one day following the closing date.

Closing of the Offering is expected to occur on or about May 24, 2017 (the “Closing Date“). The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

“The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR located in both Alberta and Ontario, including Acreage Pharms Ltd. and AB Laboratories Inc. and Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Executive Chairman

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Invictus MD Strategies Corp.

Click here to visit the Invictus MD Strategies Corp. website

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD to Open the Market at TSX Venture Exchange on May 5

Chart | Calendar   | TRADE NOW | CANNABIS

Invictus MD to Open the Market at TSX Venture Exchange on May 5

BUZ INVESTORS PRESS RELEASE  Invictus MD to Open the Market  INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (

BUZ INVESTORS PRESS RELEASE  Invictus MD to Open the Market  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) Invictus MD is pleased to announce that its management team will visit TSX Venture Exchange (TSXV) on May 5, 2017 and will be opening the trading day.

“When we open the trading day, we share this celebration with all those who have contributed to our success – especially our team, the board, advisers and investors,” said Dan Kriznic, Executive Chairman of Invictus MD.  “From our early beginnings three years ago, with a clear goal and the desire to do something remarkable within this budding marketplace, we raised sufficient capital to make investment commitments for the construction of a number of cannabis production facilities across Canada.  We have always taken pride in knowing we’re working towards becoming a source of uncompromising quality of medical cannabis and to be ready for the future new recreational market upon legalization. Now, three years later, we’re thrilled to be on Bay Street.”




Invictus MD to Open the Market

>>>TRADE NOW<<<

“The Company is poised for a tremendous amount of production profile growth and other value-generating milestones in the near future.  Cultivation has started at Acreage Pharms, having received their license to cultivate under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”),” stated Trevor Dixon, President and CEO of Invictus MD. “Planning the Phase II build out has begun; the 150 acre land package provides the capability to construct facilities to keep pace with the growing medical cannabis market and meet the demand that the coming adult recreational cannabis use will create.  AB Laboratories Inc. (“AB Labs”), a Licensed Producer under ACMPR, is on schedule to meet full production capacity by the end of May 2017.  AB Ventures Inc. (“AB Ventures”), an incorporated company formed to develop a second licensed expansion facility through its common ownership with AB Labs, closed its 100-acre land acquisition on May 1, 2017 and once licensed under the ACMPR, will be used for future cannabis cultivation.

Considering the magnitude of AB Ventures’ land holdings and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, we will have the capacity for significant growth to keep pace with the growing medical and future recreational demand.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp., Canada’s Cannabis Company, is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Bureau of Medical Cannabis Regulation Releases Proposed Regulations for Medical Cannabis

Chart | Calendar   | TRADE NOW | BMCR Bureau of Medical Cannabis Regulation Releases Proposed Regulations for Medical Cannabis BUZ INVESTORS PRESS RELEASE  Bureau of Medical Cannabis Regulation (BMCR) today announced that its proposed licensing regulations for medical cannabis have been posted and the 45-day public comment period is now underway. […]

$VPRB HONEYSTICK and Gold Nugget Extracts Place 1st, 2nd, and 3rd at the High Times Cannabis Cup

VPR Brands HONEYSTICK and Gold Nugget Extracts Place 1st, 2nd, and 3rd at the High Times Cannabis Cup BUZ INVESTORS PRESS RELEASE  VPRB HONEYSTICK   VPR Brands, LP (OTC PINK: VPRB) and Gold Nugget teamed up at the High Times Cannabis Cup So-Cal April 21-23. The entries were within the […]

$TRTC to Present at the 2017 Canaccord Genuity Cannabis Conference

Terra Tech Corp. to Present at the 2017 Canaccord Genuity Cannabis Conference on May 10th BUZ INVESTORS PRESS RELEASE  TRTC to Present Terra Tech Corp. (TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced that its Chairman and Chief Executive Officer, Derek Peterson, will present […]

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD completes acquisition of Acreage Pharms Ltd. a Licensed Producer of Cannabis under the ACMPR

 

Invictus MD completes acquisition of Acreage Pharms Ltd. a Licensed Producer of Cannabis under the ACMPR

 

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

BUZ INVESTORS PRESS RELEASE  Invictus MD completes acquisition  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has acquired 100% of the shares of Acreage Pharms Ltd. (“Acreage Pharms”), a licensed producer of Cannabis under the Access to Cannabis for Medicinal Purposes Regulations (“ACMPR”).

The Company is pleased to announce the appointments of the vendors to the Company’s management team.  Trevor Dixon has been appointed director and Chief Executive Officer of the Company and Brenda Dixon has been appointed the Chief Science Officer of the Company.  Dan Kriznic will continue his leadership role as Executive Chairman of the Company.

“This is an exciting day for Invictus MD, and our shareholders.  With the Company’s acquisition of 100% of Licensed Producer Acreage Pharms in Alberta, we now have 250 acres of cultivation space that stretches from Alberta to Ontario. Acreage Pharms will benefit from a low cost of production as a result of low energy and water costs. Additionally the property is friendly to building as many square feet as required based on the significant demand, which Deloitte reports to be between $4.9 billion and $8.7 billion annually.  I’m also very pleased with Trevor’s appointment as CEO, a highly successful entrepreneur and businessman, and also with Brenda’s appointment.  Invictus MD is fortunate to have both of the Dixons on board, in capacities that will see the Company continue to rapidly expand in the burgeoning cannabis sector. We are Canada’s Cannabis Company,” said Kriznic.

Invictus MD completes acquisition 

“I’m passionate about researching and producing products that have the potential to improve the quality of life for fellow Canadians and am very pleased to be a part of this amazing industry, Invictus MD, and its team of forward thinking professionals.” stated Trevor Dixon, President and CEO.

The Company and the vendors amended the composition of the purchase price for Acreage Pharms concurrently with closing to: (i) decrease the share consideration by one million shares, to 20 million common shares; and (ii) increase the cash consideration by $2 million, to $6 million.  The terms of the three million warrants issued to the vendors with an exercise price of $1.50 per warrant, of which one third will expire every six months on the anniversary of closing, were not changed.  Please see the Company’s news release dated February 24, 2017 for additional information.

Canada’s cannabis industry could reach $22.6 billion over the coming years, according to Deloitte, of which the retail market could be worth up to $8.7 billion. With only 43 producers licensed by Health Canada thus far, there’s a significant market opportunity for Invictus MD to capitalize on this growth over time.  The Company has focused on building its production profile, which includes:

AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the ACMPR, has successfully conducted test crops and is currently operating at half capacity, with full production capacity scheduled by the end of May 2017. They have also acquired a number of different strains and are negotiating numerous others for R & D purposes.

AB Ventures Inc. (“AB Ventures”) 100-acre acquisition is scheduled to close on May 1, 2017, which once licensed under the ACMPR, will be used for future cannabis cultivation. Invictus MD has made a commitment to invest $5.5 million, which will be used to fund the costs of licensing approval under the ACMPR and the initial construction of 42,000 square feet. Considering the magnitude of AB Ventures’ land acquisition and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, the combined production capacity of both AB Labs and AB Ventures is expected to exceed 25,000 kilograms in 2020.

Acreage Pharms has constructed a 6,800 square foot production facility and has an expansion plan floor plate of 30,000 square feet, with an option to add a mezzanine. The large 150-acre land package provides the capability to construct facilities to meet the demand that the coming adult recreational marijuana use will create. Acreage Pharms also has plans to produce extracted or oil based products, which are rapidly gaining market share in the cannabis sector. By 2020, Acreage Pharms anticipates production to exceed 25,000 kilograms of high quality, low cost cannabis.
“From day one, we have been very clear: to acquire and grow production capacity under the ACMPR that would allow us to seize the recreational market, when available, was the key driver to increasing shareholder value”, said Dan Kriznic. “Given our ability to aggressively expand the commercial scale of the Acreage Pharms property, we will make key capital investments that enable us to rapidly ramp up production capability.”

Canada is on the global stage for cannabis legalization and moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for responsible adult consumption and we welcome the regulatory framework around legalization while reducing access for underage Canadians, keeping profits out of the hands of the black market, and ensuring that customers are protected by having access to clean and safe product. This is of utmost importance, given the expected demand that will come with cannabis legalization for the recreational market.

We embrace the role we will play in the establishment of a secure environment for the continued development of a new cannabis economy that will generate even greater investment, innovation, economic development and job creation to many locations across Canada.

As Canada embarks on this historic and brave path, Invictus MD looks forward to working alongside all levels of government to achieve its goal of keeping cannabis out of the hands of youth and establishing a legitimate market while eradicating the black market.

In connection with the closing, the Company issued to an arm’s length finder a fee consisting of common shares and cash based on 5% of the consideration paid in this transaction.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms

 

BUZ INVESTORS Invictus MD announces $40,000,000 Bought Deal INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) announced today that it has engaged Canaccord Genuity Corp. and Eventus Capital Corp
BUZ INVESTORS  Invictus MD announces $40,000,000 Bought Deal INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announced today that it has engaged Canaccord Genuity Corp. and Eventus Capital Corp., as co-lead underwriters and joint-bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, subject to adjustment pursuant to the Underwriters’ Option (as hereinafter defined), $40 million aggregate principal amount of convertible debentures (the “Convertible Debentures”) at a price of $1,000 per Convertible Debenture (the “Offering”).Invictus MD has also granted the Underwriters an option (the “Underwriters’ Option”) to purchase up to an additional $10 million aggregate principal amount of convertible debentures on the same terms as the Convertible Debentures pursuant to the Offering (together with the Convertible Debentures, the “Debentures”). If the Underwriters’ Option is exercised in full, the aggregate gross proceeds of the Offering will be $50 million.




 Invictus MD announces $40,000,000 Bought Deal

The Debentures will bear interest from the date of closing at 8% per annum, payable semi-annually on June 30 and December 31 of each year. The Debentures will have a maturity date of 24 months from the Closing Date of the Offering (the “Maturity Date”).  Net proceeds from the Offering will be used primarily towards expansion and growth opportunities.

The Debentures will be convertible at the option of the holder into common shares of the Company (“Common Shares”) beginning on the date that is four months following the Closing Date and any time prior to the close of business on the Maturity Date at a conversion price of $2.00 per Common Share (the “Conversion Price”). Beginning on the date that is four months and one day following the Closing Date, the Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price on 30 days’ prior written notice should the daily volume weighted average trading price of the Common Shares be greater than $3.35, for any 10 consecutive trading days.

The Debentures will be subject to redemption, in whole or in part, by the Company at any time after 12 months upon giving Debenture holders not less than 30 and not more than 60 days’ prior written notice, at a price equal to the then outstanding principal amount of the Debentures plus all accrued and unpaid interest up to and including the redemption date. Upon a change of control of the Company, holders of the Debentures will have the right to require the Company to repurchase their Convertible Debentures, in whole or in part, on the date that is 30 days following the giving of notice of the change of control, at a price equal to 100% of the principal amount of the Debentures then outstanding plus accrued and unpaid interest thereon (the “Offer Price”). If 90% or more of the principal amount of the Debentures outstanding on the date of the notice of the change of control have been tendered for redemption, the Company will have the right to redeem all of the remaining Debentures at the Offer Price.

The Debentures and any Common Shares issuable upon conversion or exercise thereof, as applicable, will be subject to a statutory hold period lasting four months and one day following the closing date.

Closing of the Offering is expected to occur on or about May 9, 2017 (the “Closing Date”). The Offering is subject to certain conditions including, but not limited to, completion of the acquisition of Acreage Pharms, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

Notice of Intention to Exercise Option

The Company is also pleased to announce that further to its news release dated February 24, 2017, it has provided Acreage Pharms Ltd. (“Acreage Pharms”), a licensed producer of Cannabis under the Access to Cannabis for Medicinal Purposes Regulations (“ACMPR”), with notification that it intends to exercise its option to acquire 100% of Acreage Pharms’ shares from its current shareholders (the “Vendors”).

The consideration to be paid to the Vendors in connection with the exercise of the option is as follows: (i) a cash payment of $4 million; (ii) 21 million common shares; and (iii) 3 million warrants with an exercise price of $1.50 per warrant, of which: one third of the total number of warrants issued will expire every six months from the date of closing.

Canada is on the global stage for cannabis legalization and moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for responsible adult consumption and we welcome the regulatory framework around legalization while reducing access for underage Canadians, keeping profits out of the hands of the black market, and ensuring that customers are protected by having access to clean and safe product. This is of utmost importance, given the expected demand that will come with cannabis legalization for the recreational market.

We embrace the role we will play in the establishment of a secure environment for the continued development of a new cannabis economy that will generate even greater investment, innovation, economic development and job creation to many locations across Canada.

As Canada embarks on this historic and brave path, Invictus MD looks forward to working alongside with all levels of government to achieve its goal of keeping cannabis out of the hands of youth and establishing a legitimate market while eradicating the black market.

The Offering is in the form of a bought deal private placement (i) in Canada to “accredited investors” within the meaning of National Instrument 45-106 and other exempt purchasers in each province of Canada, as agreed upon by the Issuer and the Underwriters, (ii) in the United States in accordance with exemption to the registration requirement under applicable United States securities law, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the common shares, Warrants, Warrant Shares of the Issuer.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR located in both Alberta and Ontario, including Acreage Pharms Ltd. and AB Laboratories Inc. and Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Moves To TSX Venture Exchange

Invictus MD Moves To TSX Venture Exchange

 

BUZ INVESTORS Invictus MD Moves - INVICTUS MD STRATEGIES CORP. <span data-recalc-dims=(TSXV:IMH) ("Invictus MD" or the "Company"), Canada's cannabis company, is pleased to announce t" width="300" height="195" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/InvictusLogo.jpg?resize=300%2C195 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/InvictusLogo.jpg?w=743 743w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS Invictus MD Moves   – INVICTUS MD STRATEGIES CORP. (TSXV:IMH) (“Invictus MD” or the “Company”), Canada’s cannabis company, is pleased to announce that its common shares will be delisted from the Canadian Securities Exchange after the close of trading on March 30, 2017 and will be listed on the TSX Venture Exchange (“TSXV”) commencing at the open of trading on March 31, 2017.  There will be no interruption in trading and the Company’s trading symbol “IMH” will remain the same.

Invictus MD’s move from the CSE to the TSXV follows a year of significant achievements.  We now have 250 acres of cultivation space that stretches from Alberta to Ontario. Invictus MD’s option to now acquire 100% of Acreage Pharms Ltd. in Alberta the site of our Licensed Producer facility which has low cost of production as a result of low energy and water costs. The property is friendly to building as many square feet as required based on the significant demand. The CEO of Acreage Pharms is a serial entrepreneur and has been successful in previous ventures.




 

OTHER STORIES BUZ TRADERS FOLLOW

Invictus MD Moves

“As one of the few cannabis producing companies in North America listed on a major exchange such as the TSX-V, this move will enable us to engage a wider investor audience,” said Dan Kriznic, Chairman & CEO, Invictus MD. “The TSX-V is the stock exchange for many of Canada’s publicly traded Licensed Producers, and we hope that the addition of Invictus MD helps to continue to signal that the view of cannabis has changed,” added Kriznic. “This is a significant day for our Company, our sector and investors. We are strongly focused on building our shareholder value, and will continue the disciplined but agile execution of our business strategy to solidly expand our position as Canada’s Cannabis Company.”

In connection with the TSXV listing, the Company has made an undertaking to the TSXV that no foreign operations will be undertaken by Invictus or any of Invictus’ subsidiaries until the approval of the TSXV for such operations is received. Invictus will undertake to the TSXV that, for so long as any securities of Invictus are listed on the TSXV, Invictus and its subsidiaries will only conduct the business of the production, sale and distribution of medicinal marijuana in Canada pursuant to one or more licenses issued by Health Canada in accordance with applicable law, unless prior approval is obtained from the TSXV.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Announces OptionCo Has Received its License to Cultivate under ACMPR

Invictus MD Announces OptionCo Has Received its License to Cultivate under ACMPR

 

BUZ INVESTORS OptionCo Has Received its License INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (CSE: IMH; OTC: IVITF; FRA: 8IS) announces that OptionCo

BUZ INVESTORS OptionCo Has Received its License  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) announces that OptionCo has received its license to cultivate under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) as Acreage Pharms Ltd. (“Acreage Pharms”).

“This is a historic day for our Company, our sector and investors” said Dan Kriznic, Chairman & CEO, Invictus MD. “We are Canada’s Cannabis Company. We now have 250 acres of cultivation space that stretches from Alberta to Ontario. Alberta has low cost of production as a result of low energy and water costs. The property is friendly to building as many square feet as required based on the significant demand. The CEO of Acreage Pharms is a serial entrepreneur and has been successful in previous ventures. He will be a key addition to the Invictus MD team. As one of the few cannabis producing companies in North America approved under the ACMPR this will enable us to engage and satisfy a wider investor audience, strengthening the sector and bring Invictus MD to international institutional investors.”



OTHER STORIES BUZ TRADERS FOLLOW

OptionCo Has Received its License

The Company now has 30 days to exercise its option under the definitive option agreement. The terms of this agreement include an issuance of 21 million shares of the Company, $4 million in cash to the current shareholders of Acreage Pharms and 3 million warrants exercisable at $1.50 per share. The Company has also committed $6 million from its treasury for building expansion at Acreage Pharms. The expansion includes a 30,000 square foot floor plate plus mezzanine within the existing 60,000 square foot secured perimeter located on the 150 acres in Edson, Alberta.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )